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1. Introduction 
Cancer is the second leading cause of death worldwide. According to the World Health 
Organisation (WHO), 12,5% of all deaths every year are caused by cancer (WHO, 2006). This is 
more than the total percentage of people who die from AIDS, tuberculosis and malaria, put 
together (International Union Against Cancer [UICC], 2007). Frightening fact is that deaths 
from cancer are projected to steadily rise. From about 7,5 million of cancer deaths, registered in 
2005, this number will likely to reach 9 million, in 2015, and about 11,5 million, in 2030 (WHO, 
2006). On the other hand, the knowledge about the causes of cancer and interventions to 
prevent and manage cancer are also growing up very fastly. At the current level of knowledge, 
it is estimated that up to one third of the cancer burden could be reduced if strictly 
implemented preventive strategies aimed at reducing the exposure to cancer risks, and 
another third of this burden could be cured if detected cancer early and treated adequately. 
The term “cancer control“ was coined to unify public health actions aimed at implementing 
evidence-based strategies for cancer prevention, early detection and treatment, however 
adapted to different socioeconomic, cultural and resource settings (WHO, 2006). WHO and its 
cancer research agency, the International Agency for Research in Cancer (IARC), provide 
coordination and the leadership in these international actions (WHO, 2006).  
2. Cancer as a common ageing disease; The risk factors paradigm  
2.1 Cancer as a common ageing disease 
Modern societies are characterised by a domination of chronic noncommunicable diseases in 
morbidity and mortality causes, including cardiovascular diseases, some cancers, chronic 
respiratory diseases, diabetes and dementia. This is partially a consequence of the decline in 
acute infectious diseases, due to improvements in life conditions, sanitation and medical 
care, and partially of the fast spread of modern lifestyles, due to urbanisation, globalisation 
and technology progress (Pearce, 1996, as cited in Majnarić-Trtica, 2009). Modern lifestyles 
include increased consumption of processed foods enriched in saturated fats and sugars, 
smoking cigarettes due to market orientation of tobacco industry, reduced leisure time, use 
of automobiles for transportation, and increased availability of electronic entertainment and 
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communication media, all contributing to a sedentary lifestyle and weight gain (American 
Cancer Society [ACS], 2002).  
To prevent diseases, it is necessary to identify and deal with their causes. In the case of 
chronic noncommunicable diseases, that means identification of health risks that underlie 
these diseases (Venkat et al, 2010; WHO, 2009). Most important, in this issue, is that a 
particular disease is caused by multiple risk factors and that, in turn, many risk factors are 
associated with more than one disease. So, by targeting certain risks, it is possible to reduce 
the burden of several diseases (WHO, 2009). This observation is in line with the results of 
the Human Genome Project showing that there is no specific disease susceptibility 
genotype, yet numerous genetic variants account for many age-related phenotypes (Collins 
& McKusick, 2001, as cited in Majnarić-Trtica, 2009; Yang et al., 2003, as cited in Majnarić-
Trtica, 2009). That means that the symptoms and signs of common chronic diseases arise 
from the complex interactions, taking place over time, among multiple genetic variants and 
environmental risk factors, shared between clinically related diseases (Buchanan et al., 2006, 
as cited in Majnarić-Trtica, 2009; Yang et al., 2005, as cited in Majnarić-Trtica, 2008a). The 
main mechanism through which an organism responds to external environmental signals 
was found to be an epigenetic control of genome function in somatic cells (Jaenisch & Bird, 
2003, as cited in Majnarić-Trtica, 2008a; Sandovici, 2008).  
2.2 The risk factors paradigm  
Importantly, when planning preventive activities, is to understand that each risk factor has 
its own causes. In fact, there is a complex chain of events enabling many entry points for 
intervention (WHO, 2009). In the proximity, there are more direct causes of the diseases. 
Factors located further in the back, act through intermediary mechanisms, to produce these 
proximal factors. Causally most distal factors have their background in social conditions 
and are hardly recognisable. However, if modified, these background causes are likely to 
have amplifying effects, by influencing multiple proximal effects (WHO, 2009). Keeping this 
in mind can help health workers and policy makers to realise that besides individually 
oriented preventive measures, population-based strategies are of the greatest importance if 
they want to reduce health risks in a community (American Cancer Society, 2002; WHO, 
2009). That means that an individual choice, regarding health-related behaviors, occurs 
within a community context that can be either facilitating, or interfering with these 
behaviors. For example, in order to disseminate healthy diet and increased physical activity 
patterns, policy makers should implement multiple strategies at the community level, to 
ensure that all population groups have access to healthy food choices and opportunities for 
physical activity (American Cancer Society, 2002).  
Another important fact is that there is no simple correlation between economic development 
and the shift in a major disease burden, from acute infections to chronic noncommunicable 
diseases. Namely, as economic development occurs, tobacco and alcohol use and obesity 
increase, followed by the burden of chronic diseases, in decades later. However, mortality 
and morbidity from chronic diseases do not start to decrease until very high level of social 
and economic development is reached (Derek et al., 2011). In other words, only at a high 
level of awareness about chronic diseases, governments and policy makers are likely to 
respond on negative trends in health behaviors, by using a range of policy instruments to 
revert these trends. It is not surprisingly then, that in the coming decades, the burden from 
chronic diseases is projected to rise, particularly fast in the developing world (Daar et al., 
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2007). However, chronic diseases do not simple replace acute infections; rather, developing 
countries experience double disease burden, that have a huge negative impact on their 
economies (Derek et al., 2011; Daar et al., 2007). 
By attributing known risk factors, including behavioural, physiological, occupational and 
environmental ones, to the total number of deaths, or the burden of diseases (measured in 
DALYs - years of life lost due to premature mortality and disability), it is possible to 
estimate of how much the burden of diseases is attributable to these selected risk factors 
(Venkat et al. 2010; WHO, 2009). Based on such analysis, it was realised that more than one 
third of the world`s deaths can be attributed to a small number of risk factors. The five top-
ranked risks include high blood pressure, tobacco use, high blood glucose, physical 
inactivity and overweight/obesity. They affect countries of all income groups: high, middle 
and low (Figure 1) (WHO, 2009). When taking into account the fact that two leading world`s 
causes of death include cardiovascular diseases and cancers, this is likely to suggest that 
avoiding tobacco and obesity, and using regular physical activity, can provide the greatest 
potential to minimise cancer risk (American Cancer Society, 2002; WHO, 2009).  
 
Fig. 1. Deaths attributed to leading risk factors, by country income level (2004) 
3. Cancer with infectious origin 
It is estimated that approximately 15% of all cancers can be attributed to viral infections. The 
oncogenic role of at least six viruses has strongly been established, including Epstein-Barr 
virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), several Human 
Papillomavirus (HPV) types, Human T-cell Lymphotropic Virus type I (HTLV-I) and 
Human Immunodeficiency Virus type I (HIV-I) (Boccardo & Villa, 2011). Cells infected by 
these viruses may turn towards oncogenesis after many years of infection latency, 
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depending on the contextual, both the host-related, and the environmental factors - the fact 
that may complicate targeting potential preventive and therapeutic approaches (Butel, 1999; 
Weinberg, 1994). On the other hand, knowledge about the ways these infections are being 
spreaded on, is likely to provide directions for instituting adequate infection control 
practices. In relation to this, it is known that some of these infections are sexually 
transmitted and can be attributed to unsafe sex and non-use of contraception. Others are 
associated with using nonsterilised injection equipment, that is either related to unsafe 
health-care, or to opiates addiction (Boccardo & Villa, 2011; WHO, 2009).  
The great opportunity for cancer prevention, at the global scale, lies in the development and 
distribution of antiviral vaccines (Schiller & Lowy, 2010). Commercially available HBV and 
HPV vaccines are already in use, and the major focus is now on their delivery, especially to 
low-income countries (Dempsey, 2010; El-Serag, 2011). The reasoning is based on the fact 
showing that HBV infection accounts for about 60% of the total liver cancer in developing 
countries, while for only about 23% in developed countries. For cervical cancer (HPV 
infection was proved as a course), the third most commonly diagnosed cancer and the 
fourth leading cause of cancer death in females worldwide, more than 85% of all cases and 
deaths occur in developing countries (Ferlay, 2010; WHO, 2009).  
4. Environmental pollution and industrial carcinogenes 
The discovery of smoking tobacco as a factor being strongly associated with lung cancer 
(more than 85% of lung cancers occur among smokers), has further emphasized the 
definition of other external factors that could probable cause cancer (that are termed 
“carcinogenes“) (American Cancer Society, 2007, as cited in Majnarić-Trtica, 2009; Pearce, 
1996, as cited in Majnarić-Trtica, 2009).  
Accordingly, at least 150 chemicals and other agents, including ionizing radiation, 
occupational (workplace) and environmental airborne particles, some drugs, as well as 
foods and other consumer products, have been listed so far by IARC, as potential 
carcinogens (American Cancer Society, 2007, as cited in Majnarić-Trtica, 2009; WHO, 2009). 
It is estimated, for example, that occupational exposure to microscopic airborne particles 
accounts for 8% of lung cancer, that is the most frequent form of occupational cancer 
(compared to 12% of deaths due to chronic obstructive pulmonary disease) (WHO, 2009). 
The encouraging fact is, however, that the majority of occupational cancers can be 
prevented, through minimising exposure, substituting safer materials, and/or enclosing 
processes and ventilation. These all are measures within the domain of engineering 
manipulation, and policy and legislation changes (WHO, 2009).  
Trends which deserve particular concern of the scientists, policy-makers and the public as a 
whole, are based on the growing number of evidence showing that long-term exposure to 
traffic-related air pollution is the risk factor which can contribute to overall and especially to 
specific respiratory and cardiovascular mortality in general population (Brunekreef et al., 
2009). Even some consumer products, including food, cosmetics and household cleaners, 
owing to their overall use, are among the most significant sources of exposure to toxic and 
carcinogenic chemicals. Higher level of awareness is the first step to tackle more adequate 
legislation and adversiting options, as well as technology innovations (American Cancer 
Society, 2007, as cited in Majnarić-Trtica, 2009; WHO, 2009).  
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5. Global cancer statistics and calls for action 
5.1 Global cancer statistics 
Based on the GLOBOCAN estimates, about 12,7 million cancer cases and 7,6 million cancer 
deaths occured worldwide in 2008 and this trend continues to rise (Jemal et al., 2011). 
Proposed major reasons include: 1) the ageing, alongside with growth, of the world 
population, as cancer affects older adults at the highest rates, and 2) an increasing adoption 
of cancer-causing behaviors, due to the processes of modernisation and globalisation (Jemal 
et al., 2011; WHO, 2009). Of this total cancer burden, 56% of the cases and 64% of the deaths 
have occured in the economically developing world. Although overall cancer incidence rates 
in the developing countries are half those registred in the developed world, the cancer 
mortality is generally similar (Jemal et al., 2011). The main reason for this dysproportion is 
in cancer survival rates, which tend to be poor in developing countries, mostly because of a 
late stage at diagnosis and limited access to timely and standard treatment (American 
Cancer Society, 2007, as cited in Majnarić-Trtica, 2008b; Jemal et al., 2011; Ebling et al., 1993, 
as cited in Majnarić-Trtica et al., 2008b).  
The most frequent cancer site diagnosed in females worldwide is breast cancer and it is also 
the leading cause of cancer death, comprising 23% of the total cancer cases and 14% of the 
cancer deaths. In general, the highest incidence rates are registered in the most developed 
regions, although 60% of the deaths occur in developing countries. Brest cancer is now the 
leading cause of cancer death among females in developing countries, a shift from cervical 
cancer which held this unfavorable position in the past decades. The second and the third 
most frequently diagnosed cancers in females are colorectal and lung cancers, the reverse 
order in cancer mortality (Table 1) (Jemal et al., 2011).  
 
Table 1. Leading cancer incidence and mortality rates, females, for more and less developed 
areas, world (GLOBOCAN 2008) 
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In males, the most common cancer site and the leading cause of cancer death is lung cancer, 
comprising 17% of the cancer cases and 23% of the cancer death (Table 2). Colorectal and 
prostate cancers are at the second and the third positions in cancer incidence and follow the 
same order in cancer mortality, with the addition of stomach cancer sharing the third 
position with prostate cancer (Jemal et al., 2011).  
 
Table 2. Leading cancer incidence and mortality rates, males, for more and less developed 
areas, world (GLOBOCAN 2008)  
5.2 Calls for action 
Based on the global cancer statistics, awareness is growing that a dramatic stride in fighting 
against cancer can be done only if initiatives are planned at the global scale. The framework 
for this call for a global action is provided in the form of basic documents, such as World 
Cancer Declaration 2006 (IUCC, 2006). According to this document, the aim is to increase the 
number of countries that have the national cancer control programs, including cancer 
prevention, early detection, treatment, palliative care and support for cancer patients. 
Cancer surveillance systems, including cancer registries, should be developed if they do not 
exist, to support data collection on cancer statistics, risk factors burden, and effects of 
measures done. Lower income countries will be especially encouraged to gain abilities for 
dealing with their growing cancer burden. In order to transfer the proclaimed aims into 
practice, international committees have established cancer control strategies (WHO, 2005, as 
cited in Majnarić-Trtica, 2008b).  
5.3 The state in EU 
In the European Union (EU27), 2,5 million of people were diagnosed with cancer in 2008 
(Ferlay, 2010). During the past decades, cooperation at the EU level showed that it is possible 
to add value, beyond the national level, to reduce cancer burden in Europe. The goal, set under 
the Commission`s “Europe Against Cancer“ programs (1987-2000), was a 15% reduction in 
cancer mortality by 2000 (Moss, 2000, as cited in Majnarić-Trtica, 2008b). Until 2003, the 
Program was at the half of this proposed pathway, with registered reduction of 9% (Boyle et 
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al., 2003). Until 2008, some of the Member States, like Finland and Luxemburg and Austria, 
have yet succeed in their efforts to reach this proclaimed goal (Cancer Society of Finland, 
2010). The horizontal approach, aimed at tackling major health cancer-causing determinants, is 
being accomplished through documents such as “European Environment and Health Action 
Plan (2004)“, set up in order to minimise work-related exposures to carcinogens and 
mutagens, and “the European Code Against Cancer“ (2003), set up to promote healthy 
lifestyles (as cited in Commission of the European Communities, 2009).  
In general, although significant advances have been made in cancer control, cancer is still a 
major public health concern in EU, accounting for 29% (3 out of 10) of deaths in men and 
23% (2 out of 10) of deaths in women (the facts for 2008) (European Commission, 2011).  
Nowadays, the situation is characterised with substantial inequalities in cancer control 
among Member States, that is illustrated with the fact that mortality from cervical cancer is 
nearly four times, and mortality from lung cancer, in men - over three times higher, in the 
worst performing Member States, than in the best ones (European Commission, 2011). In 
order to strengthen efforts to share information, capacity and expertise in cancer prevention 
and control, the European Commission has recently proposed the “European Partnership 
for Action Against Cancer“, for the period 2009-2013 (Commission of the European 
Communities, 2009).  
6. Preventive measures that can reduce the cancer burden 
Based on the experience gained so far, it is considered that a substantial proportion of the 
cancer burden worldwide could be prevented if adequately implemented community-based 
programs for early cancer detection and treatment, tobacco control, cancer-related vaccination 
(for liver and cervical cancers), and health promotion campaigns (American Cancer Society, 
2002; Commission of the European Communities, 2009; WHO, 2009) (Table 3).  
 Implementation of principles of a healthy life-style, mainly by means of a healthy 
diet - low in saturated fats and carbohydrates and high in fruit and vegetable, regular 
physical activity, no smoking, and only moderate alcohol consumtion 
 Changes in sexual behaviour (including the number of partners, partners selection, 
the type of sex involved, knowledge on infection status of partners, use of barrier 
contraceptives) 
 Immunization against Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) 
infection 
 Taking the control over occupational hazards 
 Avoidance of cancer-causing substances in the global environment and in consumer 
products 
 Avoidance of attentive exposure to sunlight  
Table 3. Primary prevention measures (taken before any sign of a disease occures) known to 
deal with the reduction in total cancer incidence  
7. Screening protocols  
The curability of cancer can be relatively high if it is detected in the early, localised stage 
(American Cancer Society, 2007, as cited in Majnarić-Trtica, 2008b; Ebling et al., 1993, as 
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cited in Majnarić-Trtica et al., 2008b). Results of randomised trials and experience of the 
countries where national programs for prevention and early detection of cancer have been 
implemented, showed that the implementation of such programs, especially when they are 
well prepared and monitored, is the most efficient and, in the long run, the least costly 
approach to fight cancer (Levin, B., et al., 2003, Nystrom, L., 2002, as cited in Majnarić-Trtica, 
2008b). Based on these facts, respective agencies, such as the American Cancer Society, 
United States Preventive Services Task Force (USPSTF), WHO, and the European Union 
Advisory Committee on Cancer Prevention (EUACCP), set up recommendations for the 
early detection of cancer (American Cancer Society Guidelines for the Early Detection of 
Cancer, 2007, The Council of the European Union Recommendation of 2 December 2003 on 
cancer screening (2003/878/EC), 2003, WHO Program on Cancer Control, 2003, as cited in 
Majnarić-Trtica, 2008b).  
In principle, these programs may be two-way oriented. One way is promotion of the early 
diagnosis by recognising the early clinical symptoms and signs of cancer, based on health 
education programs performed for both, primary health care physicians and the population 
(WHO/Cancer, 2007, Wender, R.C., 2007, as cited in Majnarić-Trtica, 2008b). The other way 
is screening of an apparently healthy population, before clinical signs of cancer are 
detectable, in order to find individuals with the early cancer or pre-cancer stages (Moss, S., 
2000, as cited in Majnarić-Trtica, 2008b). In this sense, screening procedures are considered 
as measures of a secondary prevention. There are two main approaches for targeting 
population: 1) targeting high-risk people (with a lifetime risk of getting a certain type of 
cancer of at least 20 to 25%), who are most likely to benefit from the intervention, and 2) 
targeting risk in the entire population, regardless of each individual`s risk and potential 
benefit (WHO, 2009).  
Fundamental for the screening is availability of effective (with the acceptable level of 
sensitivity and specificity), low-cost, simple for application, and safe tests. This is not 
possible for all cancer sites. Fortunately, screening tests proved so far as being feasible for 
wide implementation, correspond with some of the most frequent cancer sites. These tests 
include: high-quality mammography (for breast cancer), Pap cytology test (for cervical 
cancer) and testing for occult faecal bleeding (for colorectal cancer) (American Cancer 
Society Guidelines for the Early Detection of Cancer, 2007, as cited in Majnarić-Trtica, 
2008b). The screening of prostate cancer by using prostate-specific antigen (PSA) testing has 
not yet been established routinely on a population base, although the increasing amount of 
evidence confirms that the early detection of this main form of cancer in men considerably 
reduces mortality, increases survival, and is likely to be cost-effective (American Cancer 
Society Guidelines for the Early Detection of Cancer, 2007; The Council of the EU, 2003, as 
cited in Majnarić-Trtica, 2008b; ESMO Guidelines Working Group, 2011).  
Under the influence of the rapid technology progress and a large amount of randomised 
trials in which the validity of particular screening approaches have been assessed - 
screening methods and protocols are constantly being changed (Table 4) (American Cancer 
Society Guidelines for the Early Detection of Cancer, 2008). Efforts have also been made in 
looking for appropriate methods for the early detection of some other frequent and/or 
hazardous cancer sites, such as lung cancer, or pancreatic cancer (Harold, C.S., 2011; The Sol 
Goldman Pancreatic Cancer Research Center, 2011).  
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Table 4. American Cancer Society, Cancer Screening Guidelines (2008) 
7.1 Screening of breast cancer  
Breast is the most prevalent cancer site in women in both developed and developing 
countries, accounting for a quarter of women worldwide diagnosed with cancer (Ferlay, 
2010). The incidence continues to rise, as the combined effect of mammographic screening, 
ageing of population, and some risk factors burden, including postmenopausal hormone 
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replacement therapy, Western-style diet, obesity, and consuming alcohol and tobacco 
among women (Aebi, 2011; Warner, 2011). Although it is still the leading cause of cancer-
related deaths in women, in most Western countries, the mortality trend has been 
decreasing in recent years, partly due to the screening programs implementation, and partly 
due to the improvements in treatment (Ferlay, 2010).  
 
Table 5. Costs associated with mammography 
It is estimated that over 90% of breast cancer in women can be cured if a disease is 
diagnosed in an early stage and adequately treated (American Cancer Society Guidelines for 
the Early Detection of Cancer, 2007, as cited in Majnarić-Trtica, 2008b). Several procedures 
are routinely used to diagnose breast cancer, including clinical (breast self-examination and 
bimanual palpation of the breasts and regional lymph nodes peformed by health care 
professionals), radiological (bilateral mammography and ultrasound) and pathological 
examination (based on the core needle biopsy). Some advanced imaging techniques, such as 
MRI (magnetic resonance imaging) and digital mammography, have recently been added, 
because of high diagnostic sensitivity of these methods (Warner, 2011). However, 
mammography is the only screening method to date proved as to can reduce mortality from 
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breast cancer, and any other method can be used only as a supplement to mammography 
(Warner, 2011). For reading of mammograms, BI-RADS classification (stages 0-5) is used. 
Cases suspected on cancer (BI-RADS 4 or 5) are refered for follow up (Eberl, 2006).  
Breast cancer incidence is strongly age-dependent, with only a quarter of cases occuring 
before age 50; less than 5% before age 35 (Ferlay, 2010). Based on these facts and on the 
results from randomised trials which consistently show a 14% to 32% reduction in mortality 
from breast cancer with annual or biennial mammography in women 50 to 69 years of age, 
screening mammography is universally recommended for women 50-69 years of age, with a 
1-year, or 2-year screening interval (Nystrom, 2002, as cited in Majnarić-Trtica, 2008b; 
Warner, 2011). Some guidelines also include women aged 40-49, although data on the 
benefit to cost ratio have not yet been clarified (Table 4) (Mandelblatt, 2011; Warner, 2011).  
Based on accumulated evidence, the decision to screen, more and more involves weighting 
benefits against costs (Table 5) (Warner, 2011). In the case of screening mammography, the 
most important benefits include reduction in the risk of death and the number of life-years 
gained. Costs include the financial costs and the by-products of the screening regimen itself 
(radiation risk, pain, inconvenience and anxiety), false positive and false negative results, as 
well as overdiagnosis (leading to overtreatment) (Duffy, 2010; Warner, 2011). The ratio of 
benefit to cost varies significantly with the patient`s age and depends on some other 
patient`s characteristics, such as breasts density (Warner, 2011). New, revised guidelines for 
breast cancer screening therefore tend to be more individually oriented.  
7.2 Screening of cervical cancer  
Cervical cancer is the third most common cause of female mortality worldwide, with the 
mortality rate 10 times higher in developing countries, and 80% of new cases occuring in 
these regions, compared to the developed countries (Ferlay, 2010; Haie-Meder, 2010). This 
disparity is in connection with low level of knowledge about unsafe sex and inaccessibility 
to screening and treatment programs, for women in developing countries (Ferlay, 2010; 
WHO, 2009). The main problem, in developed countries, is still insufficient coverage of 
women in the generative age with the screening test (Commission of the European Union, 
2007; Haie-Meder, 2010).  
Cervical cytology based on Pap smears remains the cornerstone of cervical cancer 
prevention programs, although this filed has rapidly been developing due to improved 
understanding of the natural history of the disease and technology innovations, such as 
liquid-based cytology, automated interpretation of Pap smears and testing for human 
papillomaviruses (HPVs) (American Cancer Society Guidelines, 2011; ESMO European 
guidelines for quality assurance, 2010). This, on the one hand, points up the neccessity for 
establishing the uniform indicators for monitoring program performance, to enable data 
comparison across the countries, and on the other hand - leads to fast exchanges of practice 
guidelines (Table 4) (ESMO European guidelines for quality assurance, 2010).  
It is now well known that a persistent infection with sexually transmittable human 
papillomaviruses is responsible for virtually all cases of cervical cancer (Haie-Meder, 2010). 
Early age at first sexual intercourse and early pregnancies have been recognised as risk 
factors. The evidence linking HPV infection to cervical cancer has initiated the development 
of HPV DNA testing, to support more accurate risk stratification, beyond the capacity of 
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conventional Papanicolaou smear testing (Figure 2) (American Cancer Society Guidelines, 
2011; ESMO European guidelines for quality assurance, 2010). Also, primary prevention by 
prophylactic vaccination against the HPV types that are causally linked with most cervical 
cancers in Europe, HPV-16 and HPV-18, is now commercially available (Schiller & Lowy, 
2010). The high efficacy of the vaccines is expected to dramatically decrease cervical cancer, 
by preventing up to 70% of newly diagnosed cases. However, prophylactic vaccination is 
performed in young girls and it will take a time until it provides the health gains. Therefore, 
cervical screening still remains the main preventive option (Figure 2). Nowadays, situation 
is that the high cost of the vaccine prevents its widespread implementation, which may 
further increase the gap in cervical cancer statistics between developed and developing 
countries (Haie-Meder, 2010).  
 
Fig. 2. Combined strategies to decrease cervical cancer 
7.3 Screening of colorectal cancer 
Cancers of the colon and rectum altogether are the third most common cancer type in the 
world and the most common newly diagnosed cancer in EU (Ferlay, 2010). In general, 
incidence is increasing along with industrialisation and urbanisation and is slightly higher 
in western and central, than in northern and southern and eastern Europe (Labianca, 2010).  
Five-year survival rates, after the disease is detected, is much worse in the Eastern European 
countries, then in the developed countries (34%, compared to 54% and 65%, in the Western 
European countries and the USA, respectively) (Ferlay, 2010). As the result of the early 
detection programs implementation in many EU countries, in past decades, five-year 
survival rates show more favourable trends in all regions of Europe, compared to as it was 
before (Labianca, 2010).  
Strong genetic influence can be attributed to only 5%-10% of colorectal cancers cases, due to 
either polyposis or non-polyposis syndromes, while the majority of cases occur sporadically 
(Balmana, 2010). The most important exogenous factors identified so far include: western-
style diet and low physical activity, smoking tobacco and inflammatory bowel diseases, 
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while the effect of chronic use of non-steroidal anti-inflammatory drugs for the prevention 
or regression of colorectal adenomas, has not yet been strongly confirmed (Labianca, 2010).  
If take into account fact that a 10-35 years long-lasting period is needed for the transformation 
of benign adenomas to cancer, it seems reasonable to expect that the systematic 
implementation of the programs of active searching for subjects with localised cancer or pre-
cancer lesions, could substantially reduce colorectal cancer mortality rate in population. It is 
estimated that under these conditions, colorectal cancer could reach a high cure rate of 80% 
and more (Winawer, 2003, as cited in Majnarić-Trtica, 2008b). This makes colorectal cancer an 
ideal candidate for screening. Since about 70% of patients are >65 y of age and the disease is 
rare under the age of 45 (2 per 100 000/y), target groups for screening usually include 
population aged 50-74y, with the minimum recommendations for the age range 60-69y 
(American Cancer Society Guidelines, 2011; Labianca, 2010). In order to complement 
community-based screening programs for breast and cervical cancers, established in many EU 
countries several decades ago, the EU Commision set up in 2003 recommendations for early 
detection of colorectal cancer, and the action plan “Europe against Colon Cancer“, based on 
“the Brussels Declaration“ (IUCC/Interantional Union against cancer, 2007, WHO/WHO 
Cancer Control Strategy, 2005, as cited in Majnarić-Trtica, 2008b).  
 
*Based on an uptake rate of 78% 
Fig. 3. Predicted outcomes of screening on colorectal cancer (according to NHS.UK, 2011) 
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Up to date, two strategies have been available: faecal occult blood test (FOBT) and 
endoscopy (colonoscopy or proctosigmoidoscopy) (American Cancer Society Guidelines for 
the Early Detection of Cancer, 2007, BMJ Clin Evid Concise/Colorectal cancer screening, 
2006, as cited in Majnarić-Trtica, 2008b; Labianca, 2010). Experiences on using the 
conventional screening method, the Faecal Occult Blood Test (FOBT), applied in 
asymptomatic population at average risk, showed that 3-5% subjects with positive results 
are to be expected (Winawer, 2003; Bond, 2006, as cited in Majnarić-Trtica, 2008b). The 
rationale for its use is based on the fact that, at an early stage, a colorectal tumour causes 
minor bleeding which can not be seen with the naked eye. The purpose of the screening is to 
check for this hidden blood in the stool sample. Recently introduced, the Faecal 
Immunochemical Test (FIT), has been shown as simpler for use and of a better specificity, 
however, because of higher price and the lack of efficiency analysis, it has not been yet 
widely implementated (American Cancer Society Guidelines, 2011). In most 
recommendations, the FOBT is used as a standard screening method, and a colonoscopy - 
for follow-up of test-positive cases. Based on widely obtained data, 10-15% of those subjects 
referred to colonoscopy are expected to be diagnosed as cancer and 30-40% as adenomas 
(Figure 3) (American Cancer Society Five-Year Relative Survival Rates, 2007, as cited in 
Majnarić-Trtica, 2008b; NHS.UK, 2011). Experiences until now showed that if screening 
strategies are implemented as organised programs based on the screening interval of 1-2 
years, it is possible to reduce mortality rate for 18% -33% (Achkar, 2006, as cited in Majnarić-
Trtica, 2008b).  
7.4 Screening of prostate cancer 
Prostate cancer is one of the three major cancer sites in men; commonly occures after 50 
years of age, with incidence progressively increasing in later decades of life. Only males 
with positive family history of a disease (at least one blood relative: father, grandfather, or 
brother) are at a higher risk even in age before 50 (American Cancer Society Guidelines for 
the Early Detection of Prostate Cancer, 2011; ESMO Guidelines Working Group, 2011).  
Screening protocol include digitorectal examination (DRE) and PSA (prostate-specific-
antigen) measuring in serum, in patients aged ≥50 years, in those who refer symptoms of 
prostatism and urinary tract disorders, or in those who require screening. The decision on 
whether or not to have a prostate biopsy (performed by transrectal ultrasound, TRUS) 
should take into account PSA parameters, such as free (f) PSA, fPSA/PSA ratio, DRE 
findings, prostate size, patient age, comorbidities, patient values and history of previous 
biopsy (American Cancer Society Guidelines for the Early Detection of Prostate Cancer, 
2011; ESMO Guidelines Working Group, 2011).  
Although there are evidence indicating that population-based screening may reduce 
prostate cancer mortality by approximately 20%, patients should have an opportunity to 
make an informed decision on whether to be screened or not, since there are some 
uncertainties associated with prostate cancer screening (American Cancer Society 
Guidelines for the Early Detection of Prostate Cancer, 2011; ESMO Guidelines Working 
Group, 2011). Namely, screening increases prostate cancer incidence, including subclinical 
forms that will not develop during life, leading to unnecessary manipulation and 
overtreating. Long prospective studies, and cost-effectiveness and quality of life analyses, 
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which are now under way, are expected to justify decisions on population screening on 
prostate cancer.  
8. Programs of early cancer detection  
In a general sense, screening program means systematic examination of the defined target 
population at average risk for developing some hazardous disease or undesirable medical 
event, or using scientifically justified tests that are appropriate to be applied as a public 
health measure (Table 6). Screening is organised periodically and at a long run, with the 
clearly defined aim to reduce the population burden of a disease and its unfavourable 
effects on the national health care system and economy. All activities in the program are 
fairly planned in an advance and performed according to the up to date standards of a 
medical care, with external finance assured. They include several subsequent steps, from 
promotional and educational activities, to screening, and a referal of subjects tested positive 
for further diagnostics and treatment. In concern to cancer, the early detection program is 
tending to become a part of more comprehensivelly shaped national strategies for cancer 
control, including also primary prevention and health promotion, as well as rehabilitation of 
cured patients, and palliative care for patients with infaust prognosis (WHO/Cancer, 2006). 
A programed approach has been proved as more efficient than the opposite one - an 
opportunistic approach - based mostly on patients demand, or performed in a diagnostic or 
clinical context. In the latter case, examinations may or may not be performed according to 
the public screening policy (Cancer screening in EU, 2007).  
There is a wide consensus that a minimum degree of public responsibility, organisation and 
supervision, is required, for screening activities to be considered as within the context of a 
program, in opposite to a “non-program“ screening. To qualify as a program, there should 
be a public screening policy documented in a law, or an official regulation, directive, or 
recommendation. As a minimum, the policy should define the screening test, the 
examination intervals, and the group of subjects eligible to be screened, including finance 
from public sources, or a co-payment. In a reality, substantially more organisational 
elements are needed to qualify screening activities as an “organised program“. These 
elements provide for supervision and monitoring of most steps in the screening process, as 
well as comprehensive guidelines and rules to define standard operation procedures. In fact, 
differentiation of “organised“ from “unorganised“ programs should take into account the 
continuous gradient, ranging from poorly organised to highly organised programs. Further, 
a team, or the body, declared as being responsible for program`s implementation and 
coordination, can be organised at the regional or national level. Programs may be further 
differentiated as to whether they are population-based or non-population-based. 
Population-based programs generally require a high degree of organisation and that, in each 
round of screening, subjects from the taget population are individually identified and 
personally invited to screening. Finally, in the case of population-based screening, program 
implementation may be in various stages of development: planning phase, pilot phase, 
rollout ongoing, or rollout complete (i.e. fully established) (Figure 4) (Cancer screening in 
EU, 2007).  
During last decades, evidence has been gained, in several countries in Europe, including 
Finland, Sweden, UK and Netherlands, which programs were performed to give 
possibilities for quality and effectiveness evaluation, on the benefits when implemented 
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organised programs for early cancer detection (Cancer Society of Finland/Screening 
programme, 2011).  
 the condition is an important health problem 
 its natural history is well understood 
 it is recognisable at an early stage 
 treatment is better at an early stage 
 a suitable test exists 
 an acceptable test exists 
 adequate facilities exist to cope with abnormalities detected 
 screening is done at repeate intervals when the onset is insidious 
 the chance of harm is less than the chance of benefit 
 the cost is balanced against benefit 
Table 6. Ten principles which should govern a national screening program (by Wilson and 
Jungner of the WHO, 1968) 
 
Fig. 4. Screening programs implemantation in the EU, breast and colorectal cancers, for 
usual target groups 
Until 2007, 22 Member States (out of 27) have adopted policies aiming for implementation of 
population-based screening programs, 11 of them in which nationwide rollout of 
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population-based programs is complete, 7 in which it is ongoing, and 4 in which it is being 
piloted or planned. Cervical cancer screening programs were running or being established 
in 25 of the Member States, but in comparison to the situation with breast cancer screening, 
program implementation varies more markedly and there is a substantial deviation from the 
recommendations of the Council of the EU. Compared to the prior two, colorectal cancer 
screening programs were running or being established in a smaller number of the Member 
States, program implementation was less advanced, and a smaller proportion of the 
population, specified in the Council Recommendations, was targeted (Figure 4) (Cancer 
screening in EU, 2010).  
8.1 Programs of some European countries  
8.1.1 Finland 
In Finland, population-based cancer screening has a long tradition, as started in the far 1963 
with cervical cancer screening (Cancer Society of Finland/Screening programme, 2011). 
Over the years, this program has come under the scrutiny, and now serves as a gold 
standard for evaluation of screening programs` quality and effectiveness. Two other main 
cancer screenings, for breast and colorectal cancer, are also being carried out in a highly 
organised manner. The first started in 1987, and the latter in 2004, after the EU Commission 
set up in 2003 its recommendations for strenghtening the efforts over early detection of 
colorectal cancer. The Mass Screening Registry provides evaluation of the impact of 
screening programs on cancer-related mortality and of the quality of the screening 
programs, and is a complementary to the Finnish Cancer Registry. The Finnish Cancer 
Registry is currently included in the European trial on prostate cancer screening.  
Screening programs are centrally directed by the Cancer Society of Finland, but it does not 
exclude regional societies to work independently and to adjust programs to different local 
environments. These regional organisations provide a vast array of services, including 
counselling units, ambulatory cancer clinics, laboratories and hospices, as well as 
organisation of rehabilitation and recreational courses. Patient organisations and numerous 
volunteers, joined as members, provide the popular base to the Societies. The Cancer 
Society, together with the Cancer Foundation and the Foundation for Cancer Research, as 
private, non-profit investors, provide the sources of funds aimed at preventing cancer 
through research, health promotion and mass screenings. The Society also actively 
participates in creating health policy. In this way, the Cancer Society has become a vast 
forum for providing a support to comprehensive cancer control, by bringing together 
scientists, clinicians, decision-makers, financial experts, volunteers and patients, in the 
common mission of reducing the cancer burden in the population.  
Specifically, Finnish smoking prevention and cessation campaigns, are worth meantioning 
details. Cigarette consumption in Finland was the highest in the world, in the period 
between two wars; consequently, the lung cancer incidence in men was one of the highest in 
the world. Due to combined effect of legislative measures, health promotion activities and 
strict monitoring, smoking decreased drastically over time, and nowadays is among the 
lowest in Europe.  
By acting in this way, Finland has become one of the leading European countries in 
achieving an efficient cancer control, with the figures decline on cancer mortality and with 
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the five-year survival rates among the best in Europe. Overall, in performing public health 
activities, Finland experienced a long process of transition, from the prevailing implicit 
policies, determined by commercial and fiscal interest, to explicit - health-oriented polices. 
In this context, earlier, the risk behaviour and a disease concern was considered as a medical 
and individual problem, while nowadays it is primarily considered as a public health, social 
and political issue.  
8.1.2 UK 
National cancer screening programs in UK include cervical, breast and colorectal cancers. 
For prostate cancer, there is an informed choice program - for healthy men who requires 
screening, and the risk management program - for men at higher risk for developing 
disease, due to symptoms of prostatism, or a positive family history on prostate cancer 
(NHS.UK, 2011). Cancer screening programs in UK are characterised with a high level of 
quality performance, and a large coverage of the target population, for cervical cancer 
already reaching the expected 80% (Arbyn, 2008, as cited in NHS.UK, 2011). Further, these 
programs are strictly evidence based, by means of the screening intervals, recommended 
age groups and methods used for screening. To avoid disparities for screening, community-
driven approach is prefered, while Primary Care Trusts and regional directors of public 
healths are responsible for the quality assurance. The National Office for Cancer Screening 
provides the call/recall system and coordinate all other activities (NHS.UK, 2011).  
The main shortage of this system is in using the lists of patients registered with general 
practitioners (GPs), allowing eligible individuals not covered by the health insurance, to 
drop out from the screening. The UK is an example of the cancer screening model which in a 
great part relies on the ordinary health care facilities and includes primary care teams to 
participate, by encouraging patients to screening and by keeping them informed on all the 
stages of the screening program. This model is termed as a “model service“.  
8.1.3 Hungary 
Hungary, as a state in the process of transition, is typically faced with the growing burden of 
chronic noncommunicable diseases, especially concerning cancer (Kovacs, 2011, as cited in 
Hčjz/Health in Hungary). The life expectancy, of both men and women, is significantly 
below the average of most countries in EU, with cancer at the leading position in regard to 
“potential year of life lost“ (PYLL). With the aim to reduce the overall mortality, and cancer 
mortality in particular, an organised cancer screening program, a part of the National Public 
Health Program, was launched in 2001. The official health care system is responsible for the 
program implementation, and finances are assured by the government. The program is 
coordinated and monitored by the Office of Chief Medical Officer.  
Analysis made upon the program implementation, reveales some shortcomings, similar to 
ones found in other programs with small tradition. Some of these barriers to program`s 
implementation include the lack of necessary prerequisites for screening, insufficient 
finances, and a fairly high number of screenings performed outside the organised screening 
settings. The latter phenomenon may be due to the low degree of awareness for mass 
screenings, and to the fixation upon traditional examination protocols. Further, there is a 
poor cooperation among acters within the programs, the problem in record linkage, between 
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various databases, and yet undeveloped laws on sensitive issues, such as data protection 
and patients rights (Kovacs, 2011, as cited in CJPH/Health in Hungary).  
8.1.4 Croatian national program of prevention and early detection of cancer 
Croatia is a transitional country characterised with health problems such as unhealthy 
behavior of the population and a growing burden of chronic diseases. The situation is even 
worse than it could be expected, because Croatia has recently experienced a war and fast 
political and social changes (Ebling B., 2007; Majnarić-Trtica, 2009).  
In cancer statistics, in comparison with the majority of European countries, Croatia takes 
high unfavourable position (Draft National Program, 2007). Cancer is the second mortality 
cause and accounts for every fourth case of death. Both cancer incidence and mortality rates 
are on the increase, with a sharp increase in incidence rates observed after 1997, 
consequently to the post war period (Figure 5). The most common cancer sites are the lung, 
the colon and the breast, with the prostate cancer prevailing in elderly men aged 75 and 
more.  
 
Fig. 5. Total cancer incidence and mortality rates, Croatia  
In Croatia, primary prevention and early detection of cancer have not been systematically 
performed before, except for some separate actions, carried out by the non-governmental 
organisations or professional associations (Eljuga, 2006, as cited in Majnarić-Trtica, 2008b). 
The early detection of cervical cancer, by cervical cytology, has been performing for all 
sexually active women during their visits to gynecologists (Šamija, ed., 2000, as cited in 
Majnarić-Trtica, 2008b). Clinical examination on cancer and the FOBT have become a part of 
periodical medical checks, performed by family physicians for patients aged 50 and older.  
Based on such situation and by taking into account unfavourable cancer statistics, the 
Croatian Oncology Society of the Croatian Medical Association initiated preparation of a 
Draft National Program for Prevention and Early Detection of Cancer (Draft National 
Program, 2007). The Program was published in early 2006. On behalf of the Ministry of 
Health and Social Welfare, the breast cancer screening program has started immediately that 
year. The National Program for Early Detection of Colorectal Cancer has started in late 2007. 
The Croatian Public Health Institute and its county departments coordinate and monitor 
program`s implementation, including activities such as the central call/recall system, data 
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collection and evaluation. Family medicine teams are not actively included, only in keeping 
data on responsiveness of their invited patients to screening, and in follow up of those ones 
with positive tests.  
General objectives, set up by the Program, are: to decrease prevalence of risk factors among 
the population by promotional and health educational activities, to reduce total cancer-
related mortality rates by 15% within 5 years after the Program started, to increase the 
percentage of diagnosed pre-clinical and localised cancers compared to percentage of 
advanced stage disease and to increase the early detection coverage of the population. 
Specific objectives are oriented towards improvements in diagnostics and treatment and 
standardisation of protocols (Table 7).  
 
Table 7. Croatian National Program, Recommendations for screening 
According to the Program for Early detection of breast cancer, women of the target 
population (50-69) are invited by surface mail to take preventive mammography every two 
years. Based on the planned coverage of 70%, it amounts about 280 000 women a year. BI-
RADS classification and double-blind reading performed by two experienced radiologists 
are used as methods for checking up mammograms. Cases suspected on cancer (BI-RADS 4 
and 5) are refered for follow up (Draft National Program, 2007; Ministry of health, 2006). 
In the first screening cycle (until the end of 2006), about 720 000 women were invited, the 
number exceeded the planned number of 280 000 invitations a year, with more than 1500 
newly diagnosed cases. (Experience from other European countries also showed increase in 
the cancer incidence during the first year of screening program implementation). Although 
achieved response rate of 58,5% was comparable to that in other European countries, the 
authorities are not completely satisfied with the results (Strnad, 2010). As the main barriers 
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to program implementation, wrong addresses and insufficiently checked patients lists, were 
addressed. The rate of suspicious results was lower than expected, which indicates that 
women with BI-RADS 0 should also be taken into consideration for referal to diagnostics. 
Continuous education of radiologists in reading the mammograms and acquisition of new 
equipments for the diagnostic centres, are planned improvement measures. Educational 
activities, with the aim to increase the level of awareness for screening among the 
population, and further strenghtening the knowledge and companionships, as much among 
different sectors and participants included in the Project, as among local communities, will 
be essential (Samardžić, 2007; Strnad, 2010).  
The screening protocol for colon cancer includes assimptomatic men and women aged 50-74 
years, as according to the international recommendations, in two-year check-up by the 
FOBT, and the coverage rate of at least 60%. Test-positive individuals are referred to 
colonoscopy, to determine the cause of occult faecal bleeding. Individuals from the high risk 
groups are managed following the special protocols. Specialists colonoscopists and surgeons 
from clinical hospitals, and laboratory workers and coordinators from the counties` Public 
Health Institutes, are responsible for the Program implementation. Invitation letters are sent 
by mail to home addresses. In an envelope, there are three testing-cards, instructions for 
their use, questionnaire about risk factors and an educational brochure. Invited persons are 
asked to mail testing-cards back, after they used them, together with a filled questionnaire, 
the purpose of which is to obtain information on risk factors spreading in the population 
(Draft National Program, 2007; Ministry of health, 2007).  
From the end of 2007 to the beginning of 2010, a total of 808 913 tests were distributed, of 
which only 19% were returned, 7,7% of these positive. Colonoscopy yielded 77,5% of 
pathologic findings, including 388 (5,99%) carcinomas; others were polyps (38,46%), 
hemorrhoids and diverticula (Strnad, 2010).  
8.2 How to increase screening coverage?  
One of the main problem, in mass screening programs, is how to increase the screening rates 
(coverage). This is two-sided problem. On the one side, there are problems of supply 
(program`s implementation performans), including necessary equipment, professionals, 
implement of evidence, establishment of the call-recall system, and strictly managed follow up 
(screening policy). On the other side, there is the problem of motivation of subjects from the 
target groups for screening (patients` compliance with screening). Two steps of the motivation 
process can be recognised: 1) a decision to enter the screening cycle (up-take) and a decision to 
stay in (adherence) (Flight, 2008; Smith, 2004). It is possible to affect patients` motivation (an 
internal mental process) by psychological transfer, including patients` empowerment and 
education, provided by physicians or other actors in the program (Masterson, 2006).  
8.2.1 Promotional and educational activities  
It has been recognised that the rate of up-take and adherence to screening may have a long-
term effect on screening programs effectiveness (Smith, 2004) and that both processes, 
inherent in decisions for screening, are subjected to changes, by educational and 
motivational activities (O`Neill, 2008). This is why it is important that promotional and 
educational activities precede to and/or follow mass screening programs implementation.  
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Media campaigns and promotional activities can be organised at the national or the local 
community level, initiated by policy-makers, local community authorities, or public 
health services. These activities have multifaceted aim to inform the community on: 1) risk 
factors for the most frequent cancer sites, 2) early symptoms of a disease, 3) early 
detection methods, 4) the importance of acceptance of screening (Ebling, 2006, as cited in 
Majnarić-Trtica, 2008b). More focused educational activities, oriented towards specific 
population groups, such as high-risk groups, adolescents, or workers in industry, as 
connected with occupational risk factors exposure - can be initiated and organised by non-
govermental organisations, local public health institutions, health professionals` 
associations, or cancer patients support groups (Eljuga, 2006, Ebling, 2006, as cited in 
Majnarić-Trtica, 2008b).  
Individually-oriented educational activities, for patients` groups or individuals, can be 
mostly effective if performed by primary health care workers, especially family physicians. 
In the latter case, educational activities tend to be transformed into more subjective 
cognitive tools, close to what is known as “encouragment“ and “empowerment“ of patients 
for screening. In this way, some elements of a self-decision making process, connected with 
reasoning thinking, can be tackled to change (Fig. 6) (Ackerson, 2009). In this context, it is 
important to know that there are elements of a self-decision making process that are less 
prone to change. They come from intuitive thinking, complementary to more conserved 
psyhologic structures, such as the values and attitudes.  
8.3 The role of family physicians in programs of early cancer detection  
In terms of organization, two extreme early cancer detection program forms are possible, 
either that supplied by governmental and public health institutions, or that based on the 
central role of family physicians in program`s implementation. By working at the interface 
of the health care system and the population, family physicians are in the specific position 
that enables them an opportunity to promote a vast array of preventive activities, in a pro-
active and a patient-oriented manner (Summerton, 2002). That means that the doctor 
recognises medical needs of the groups and individuals, encourages them to take 
preventive measures and manages the screening protocols, in contrast to the approach 
where the doctor generally responds to the patient`s requests. Moreover, the possibility of 
having an insight into specific characteristics of each patient, enables family physicians to 
select an appropriate way to present the preventive measures to a patient, and to create 
activities, in order to improve patient`s uptake and adherence to screening (Figure 6) 
(NHS.UK, 2011).  
There is a general assumption that prevention and early detection of cancer is insufficiently 
implemented in practice of family physicians. In most countries, family physicians are only 
partially involved, mainly through opportunistic screening (subjects are referred by a 
physician for screening outside the program supplied by public services), or only under 
certain conditions, such as rural and distant areas (Moss, 200, as cited in Majnarić-Trtica, 
2008; NHS.UK, 2011). Randomised studies in which screenings on cancer, managed by 
family physicians, were explored, are scared and not of a large-scale, to allow general 
conclusions to be drawn on (Jellema, 2010).  
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Fig. 6. Decision stages for colorectal cancer (CRC) screening 
8.3.1 Experiences from Croatia in involving family physicians in programs of early 
cancer detection 
The leaders of the Department of Family Medicine of the Osijek University School of 
Medicine and the Health Center Osijek, have recently introduced the project “A Model of 
Early Cancer Detection Integrated in Practice of Family Physicians“, to test the idea that 
screening and early diagnosis of cancer are more efficient if integrated in practice of family 
physicians, compared to the National Program, centrally directed and supplied by the 
public services (Ebling/Project, 2007, as cited in Majnarić-Trtica, 2008b). The Project has 
started after two years of preparations and education of subjects from the target groups and 
family physicians, included in the Project, on screening and early detection methods. The 
computer program, specifically designed for keeping the records on data and for follow up 
of patients with positive screening tests, was installed into a total of twenty GP offices 
included in the Project. This program has allowed the continuous recruitment of new 
patients into the surveillance system automatically, by using personal data on sex and age 
only (Majnarić-Trtica, 2008b). Up to date, the Project has yielded its results in colorectal and 
breast cancer screening.  
8.3.1.1 The Project of early detection of colorectal cancer  
To avoid overalpping with the National Program, subjects were included in the Project for 
early detection of colorectal cancer to belong to either the 5-year lower age class (45-49) or 
the 5-year upper age class (75-79), than it is recommended according to the National 
Program (50-74). These defined target groups encompassed approximately 4 000 people, 
randomly selected from the large sample of a total of 27 000 subjects, recorded on the lists of 
family physicians included in the Project (Majnarić-Trtica, 2008b; Pribić, 2011).  
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The screening protocol can be described as follows. Family physicians call the patients from 
the defined target groups by phone, deliver them letters of invitation in envelops together 
with three testing cards, brochure for their use and a questionnaire on risk factors. A 
physician also provides instructions on how to correctly apply the testing cards and other 
issues the patients may be interested in. A physician reads the applied testing cards when 
patients return them back and keeps a record on the results. Patients with positive tests are 
referred for further diagnostics by colonoscopy. A physician also keeps a record on the 
results of follow up and treatments (Pribić, 2011).  
From the beginning of April to the end of May 2009, a total number of 516 testing sets on 
occult faecal blood were delivered to patients from these two defined target groups. A high 
responding rate of 69,76% (360 cases) was recorded. This was an advantage in comparison 
with low responding rates of about 20%, obtained by the National Program. In the Project, 
there were in average 2,5% (13 cases) with positive tests, predominantely in the older age 
group, 3,5% (11 cases), compared to 1% (2 cases) recorded in the younger age group. These 
results showed that in the middle age population groups (45-49), a very low rate of positive 
tests, in systematically and non selectively performed screening on occult faecal bleeding, 
might be expected (1% positive tests). This further indicates that, for younger population 
groups, a selection of subjects at higher risk for the development of colon cancer should be 
made, prior entering the screening cycle.  
8.3.1.2 The Project of early detection of breast cancer 
The study group comprised the women from ten GP offices who have not yet been invited 
by the County Institute of Public Health to screening with mammography (Pribić, 2010). 
These women were invited during their visits for reasons other than mammography 
(opportunistic screening), or actively, by surface mail or phone. Women who did not 
respond at the first invitation, were included in the four-phased motivation program, 
carried out by a family physician and a home visiting nurse. If their decisions remaind 
unchanged after the period of three months of follow-up, they were classified as resisted the 
screening with mammography. Although a high level of responsiveness, of 80%, was 
achieved, a critical appraisal upon this study includes a suggestion for the post-hoc testing, 
to decide on whether a long-lasting and highly suggestive motivation activities are 
applicable as a routine advising procedure. In addition, results obtained here indicate, 
similar as in the case with the Project of early detection of colorectal cancer, that there is a 
need for more thoroughly prepared selection procedure, before someone starts motivating 
women to screening.  
8.3.2 Concluding remarks 
A central role of family physicians, in implementation of preventive programs, has been 
recognised as an advantage, in terms of achieving better screening coverage and 
decreasing the costs, as compared to the strictly centrally controlled programs. However, 
as with the respect to the above results - even those who advocate for this approach, must 
point out that some kind of technical and professional support to family physicians 
should be assured, to allow the program to maintain and to achieve high quality norms 
(Wender, 2007).  
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9. Current trends  
9.1 Personalised screening 
There is no doubt that the early detection of cancer is effective, but no clear attitudes on 
which strategy is more efficient than another, in a real situation within the framework of the 
current health care system organisation. Awareness has been increasing that variables such 
as “a benefit-to-risk“ and “a benefit-to-cost“ ratio, or „a quality of life measures“, should be taken 
into consideration when planning screening strategies (WHO, 2009; Aebi, 2011). New, more 
specific screening tests, such as a digital mammography, or immunochemical tests for 
testing on occult faecal bleeding, are now available and increase our chance to detect cancer 
early. However, higher prices of these tests, compared to conventional ones, require more 
specifically elaborated screening strategies, including a precise definition of who should be 
included in screening, by using which tests, and under which conditions (Jellema, 2010; 
Schousboe, JT, 2011; Warner, 2011). Evidence also suggests that variables such as the 
patient`s context, including co-morbid health disorders, and patient`s values, regarding 
specific benefits and harms from screening, are to be taken into account (Warner, 2011).  
9.2 Cancer risk prediction models 
The average risk of getting a cancer (for a 5-years, or a 10-years time period, or expressed as 
a lifetime risk) are estimated on the basis of the incidence data for the population. Many 
factors that can change these estimates to the higher or to the lower, for some of the most 
common cancers sites, have been identified (known as cancer risk factors) (US National 
Cancer Institute, 2010, 2011). Knowledge on this issue allows personalisation of risk 
assessments, based on the estimates such as the score charts, or mathematical risk prediction 
models, which can help physicians and policymakers to identify individuals who might 
benefit, more than some others, from the screening.  
Multivariable risk prediction models for some usual cancer sites have been established so 
far, based on using easily available epidemiologic and clinical data and identified risk 
factors. It has been realised, however, that the model`s precision can further be improved, if 
some biochemical or molecular biomarkers are added into the model or, more recently - 
information on a personal genome analysis (Barlow, 2006; Rosenbaum, 2010; Spitz, 2007, 
2008; Wang, 2007). Risk prediction models are expected to support a decision-making, 
beyond the traditional screening protocols, by more accurately identifying subjects of the 
target groups.  
9.3 Genetic risk estimates 
Two Mendelian genetic tests, appropriate to add value to the cancer risk assessment, have 
been established so far, including BRCA1 and BRCA2, highly penetrant breast and ovarian 
cancer predisposition genes, and a set of the mismatch repair (MMR) genes, carriers of 
which have a high risk of the most common hereditary colorectal cancer and/or 
endometrial cancer, and a lower risk of urinary tract, small intestine, ovary, gastric, 
pancreas, biliary tract and brain cancers (Balmana, 2010; 2011).  
The costs of the genetic tests were the main problem in the past, making the barriers for 
implementing these tests in routine practice. Nowadays, when the costs of these tests 
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rapidly fall down, the dominant problem is a lack of the clinical assessments of genetic risk 
estimates. For example, higher prevalence of BRCA 1/2 genes can be found in association 
with a family history of breast or ovarian cancer and a young age at onset (Balmana, 2011). 
Is there an added value of systematic testing on these genes, in women with a positive 
family history of breast cancer, beyond the standard screening with mammography, if 
familial susceptibility to breast cancer accounts for less than 25% of all breast cancer cases? 
This further arises some additional questions. Namely, carriers should advise close family 
members to obtain genetic counseling and/or testing (American Cancer Society/A manual 
Cancer and Genetics, 1997/98; Balmana, 2011). This is associated with some ethical and 
moral issues addressing both, potential carriers and physicians who provide counseling for 
them. The major concern addressing potential carriers includes living under the pressure of 
having an increased susceptibility for cancer. Concerns addressing physicians include low 
level of knowledge on variation in penetrance and expression of cancer-prone genes, and a 
lack of evidence of how a genetic counseling might have an impact on issues from the 
ethical domains (American Cancer Society/A manual Cancer and Genetics, 1997/98). 
9.4 The personalised approach in early cancer detection - the role of genomics and 
proteomics 
The rapid progress in biotechnology has been expected to provide huge benefits in 
prevention and early detection of chronic noncommunicable diseases, notably cancer, by 
implementing genomics, proteomics and other -omics techniques in practice. The main 
principle, these techniques relies on, is a possibility of identifying subjects at an early clinical 
or subclinical phase, during the course of developing a chronic disease, by obtaining the 
whole-genome sequencing (genomics), or by characterising the protein and peptide profiles 
of various biological fluids or tissues (proteomics) (Yang, 2003, Khoury, 2007, as cited in 
Majnarić-Trtica, 2009).  
These techniques have attracted the attention of both, the scientists and the public as a 
whole, in recent times, for their potential to stimulate the adoption of the personalised 
approach in medical practice, with expectancies for the improvements, equally in 
prevention, prognosis, diagnosis and treatment. For the reason that these techniques were 
developing far more rapidly than their clinical utility could be evaluated, there is no clear 
understanding yet, of what would be reasonable expectations of implementing these 
techniques in the real-life settings, and which obstacles need to be overcome. Although 
some early results of their clinical applications seem promising, such as the use of serum 
proteomics in screening for ovarian cancer, providing sensitivity of 100% and specificity of 
95% - to date, there are no visible results yet, capable to bring substantial changes into the 
standard routine (Evans, 2010; Ioannidis, 2011).  
10. Challenges for the future  
10.1 Integrated knowledge translation 
In spite of the huge advances in understanding the natural course of development of some 
common cancers, as well as in methods for their prevention and early detection, there are 
still difficulties in translating this knowledge into practice. The problem is especially 
emphasized in developing countries. Some of the main reasons include: separation between 
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public health and clinical medicine, poor coordination between the health care and science - 
on the one hand, and the health care and politics and social welfare - on the other, and the 
rapid progress in health care technology and biotechnology, leading to a rapid rise in health 
care costs and the disparity in access. In addition, there is a need for better integration of the 
new, individually-oriented approaches into the established early detection programs 
(Evans, 2010; Hudson, 2011; Majnarić-Trtica, 2009; Pigeot, 2010).  
There are initiatives to bridge these gaps, by favouring a collective approach to problems 
and questions concerning health. It is believed that this might be achieved through a 
leadership shift (from a traditionally top-down to a coalition leadership between 
practitionars and researchers/scientists), and the process of integration of the knowledge 
bases, among multiple health care and other social sectors. Namely, an awareness is 
growing up that the issues of public health are intimately embedded in the 
socioenvironmental context and should be managed within this context. For this reason, 
researches, public health professionals and policy decision-makers, should collaborate in 
searching for “better“, “faster“ and “cheaper“ interventions, aimed at improving the health 
in the community. The development of the common information and communication 
technology infrastructure are expected to facilitate these common initiatives (Lapaige, 2010; 
majnarić-Trtica, 2009; Patridge, 2011).  
10.2 The chronic care model  
Improvements in the early detection, diagnosis and treatment of cancer enable people with 
cancer living longer and managing their cancers as a chronic illnesses. This consideres a 
long-term surveillance, including prevention, early detection, diagnosis, treatment, care 
after the treatment, and survivorship. Demands are put on patients and their families, in 
managing care on their own, and on family physicians, in providing them education and 
support, as well as a follow up (McCorkie, 2011).  
11. Conclusions 
Experiences gathered up-to-date show that the programs for early cancer detection are best 
performed if well organised and coordinated, independently on whether they are conducted 
by governmental and public health institutiones, or predominantly supplied by family 
medicine teams. In highly income countries, with long tradition in organising early cancer 
detection programs, expected curing and survival rates have been achieved. These 
favourable results can not be attributed only to a large number of professionals employed, 
good technical facilities and government officials coordinating the programs, but, even 
partially, to the comprehensively performed and sustainable driven strategies aimed at 
cutting the common risks factors burden for the most important chronic diseases, including 
cardiovascular diseases, diabetes and cancer. In this sense, the best way to invest in 
populations` health, would be by ensuring health protective working and living 
environment (Cancer Society of Finland, 2011; WHO/Health 2020, 2011). In case of lower 
income countries, strong orientation towards primary health care in performing programs 
of prevention and early detection of cancer, could be the best solution, as it has been proved 
that better primary care resources considerable contribute to reducing the adverse impact of 
social inequalities on health (Starfield, 2011). However, good primary care (practice) 
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depends on good primary health care (system), that means that primary care is reflective of 
a specific health care system policy. This reasoning was in the background of the recent 
iniciative of the European Member States, to potentiate a wave of health reforms across 
Europe (WHO/Health 2020, 2011).  
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